.jpg)
On The Pen With Dave Knapp
Dave Knapp brings you your weekly dose of everything in the news about incretin mimetic, diabetes and obesity therapies, like Zepbound and Mounjaro, Ozempic and Wegovy, and even investigational treatments like CagriSema and Retatrutide!
On The Pen With Dave Knapp
Lilly Earnings Call Analysis: Why Zepbound Missed Earnings
Dave brings his analysis of the Q3 Eli Lilly earnings call, and how it relates to the future of access to obesity medicine. Also there is an important clarification on the Zepbound savings card that you should not miss.
#Zepbound #Mounjaro #Tirzepatide
DNF10 Peptide Supplement I Use: https://integrativepeptides.com/AFFILITATES/OTP
USE CODE "OTP10" to save 10%. A small commission is paid back to support On The Pen!
MY WORK RELIES ON YOUR GENEROSITY, WAYS TO SUPPORT:
Venmo: OnThePen
Ca$h App: ManOnMounjaro
BECOME A MEMBER:
https://www.youtube.com/channel/UCDocQ-4IhVS3ihy_dW7nSKw/join
👉 My Amazon Affiliate Store:
https://www.amazon.com/shop/manonthemounjaroonthepen
MORE COMMUNITY!
📺 Watch Our Weekly Live Show: onthepen.tv
🆕 Discord: https://discord.gg/u4Ea8qqP
🤝 Visit Our Sponsor!
GLP-1 Ro Body Plan: https://www.ro.co/otp
Report The Shortage: https://www.ro.co/supply-tracker
Does your insurance cover GLPs? https://www.ro.com/checker
📲 Contact Me: dave@onthepen.com
Thank you for tuning in! If you found this content valuable, make sure to like, share, and subscribe to my youtube channel for more updates on GLP-1, obesity, type 2 diabetes, and the latest news on Mounjaro, Zepbound, Wegovy, and Ozempic. Stay informed and entertained with my unique blend of breaking news, humor, and my personal journey. For in-depth articles and resources, visit onthepe...
